Rethinking anti-cancer drug discovery: the evolution from polypharmacy to unified drug units
Despite advances in current anti-cancer therapies, challenges such as drug resistance, toxicity, and tumor heterogeneity persist. The limitations of traditional single-target drugs and simple combination therapies are becoming increasingly apparent[1][1]. To address these issues, a novel treatment
Authors
- Jun He
- Xinbing Sui
Institutions
- Hangzhou Normal University (CN)
- Affiliated Hospital of Hangzhou Normal University (CN)
Publication Details
- Journal
- Cancer Biology and Medicine
- Published
- 2026-01-29
- DOI
- https://doi.org/10.20892/j.issn.2095-3941.2025.0641
- Citations
- 1
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 22.24